<![CDATA[This study aims to provide a comprehensive review of the genetic characteristics of acute lymphoblastic leukemia that has relapsed, discuss the relationship between interleukins and the disease, and explore targeted therapy. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines were followed in the development of the current study on acute lymphoblastic leukemia and the role of interleukins in hemato-oncology. The results reveal that relapse rates remain high and the prognosis for individuals who experience a relapse is inferior. Currently, innovative targeted medicines are employed to supplement traditional cancer treatment. The novel strategies are put into practice to lessen the load of toxicity and enhance results. From these findings, it can be concluded that combating refractory T-ALL requires the discovery of innovative medicines that directly target pathways driving Leukemia-Initiating Cell (LIC) activity.]]>
Copyrights © 2025
